Edition:
India

Nanobiotix SA (NANOB.PA)

NANOB.PA on Paris Stock Exchange

12.43EUR
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
€12.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,637
52-wk High
€22.50
52-wk Low
€11.25

Chart for

About

Nanobiotix SA is a France-based oncology focused nanomedicine company. It is engaged in developing nanoparticle technology. It develops new tools for cancer which utilize a physical mode of action at the cellular level of the cancer cell. This disruptive approach may reshape future treatment opportunities. The Company's NanoXray... (more)

Overall

Beta: 1.61
Market Cap(Mil.): €301.54
Shares Outstanding(Mil.): 17.56
Dividend: --
Yield (%): --

Financials

BRIEF-Nanobiotix Q3 revenue down at 33.0‍​ million euros

* Q3 REVENUE EUR 33.0‍​ MILLION VERSUS EUR 58.6 MILLION YEAR AGO Source text: http://bit.ly/2zKWYHz Further company coverage: (Gdynia Newsroom)

15 Nov 2017

BRIEF-Nanobiotix completes new share issue for about 27.2 million euros

* NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES

31 Oct 2017

BRIEF-Nanobiotix completes patient inclusion for phase II/III trial of NBTXR3

* NANOBIOTIX COMPLETES PATIENT INCLUSION FOR PHASE II/III TRIAL OF NBTXR3 IN SOFT TISSUE SARCOMA

23 Oct 2017

BRIEF-Nanobiotix to conduct its first clinical trial with NBTXR3 in the U.S.‍​

* PLANS TO CONDUCT ITS FIRST CLINICAL TRIAL WITH NBTXR3 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.‍​

28 Sep 2017

BRIEF-Nanobiotix H1 net loss widens to 12.2 million euros

* H1 NET LOSS EUR 12.2 MILLION VERSUS LOSS OF EUR 10.2 MILLION YEAR AGO

31 Aug 2017

BRIEF-Nanobiotix Q2 revenue down at 58,645 euros

* H1 RENTAL REVENUE EUR 91.5 MLN VS EUR 91.4 MLN YR AGO Source text: http://bit.ly/2tJ0z7p Further company coverage: (Gdynia Newsroom)

12 Jul 2017

BRIEF-Nanobiotix presents new data on NBTXR3

* ANNOUNCED ON THURSDAY PRESENTATION OF NEW TRANSLATIONAL DATA AT ASTRO, NCI AND SITC'S IMMUNOTHERAPY WORKSHOP

16 Jun 2017

Earnings vs. Estimates